Comparison of Uncomplicated Candidemia Therapy Duration in Children

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: * Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. * Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

NCT Number	NCT05763251
Lead Sponsor	Arkansas Children's Hospital Research Institute Collaborators: Westat, St. Jude Children's Research Hospital, George Washington University, Children's Hospital of Philadelphia, National Institute of Allergy and Infectious Diseases (NIAID)
Conditions	Invasive Candidiasis
Enrollment	420 participants
Start Date	2023-09-08
Primary Completion	2030-06-30 (estimated)
Study Completion	2032-06-30 (estimated)
Updated on ClinicalTrials.gov	2026-04-17